Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology [Yahoo! Finance]
Gelteq Limited - Ordinary Shares (GELS)
Company Research
Source: Yahoo! Finance
the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the appointment of Dr. Paul Wynne as its Chief Scientific Officer (“CSO”). Gelteq co-founder and CEO Nathan Givoni stated, “We believe Dr. Wynne's distinguished record and expertise in formulation science and drug delivery systems will be instrumental in driving the next phase of Gelteq's product pipeline. Recognized for his collaborative approach and ability to coordinate high-performing teams that drive scientific excellence, Dr. Wynne's pedigree aligns with Gelteq's mission to enhance health and wellness through our novel ingestible gel technology. We look forward to further strengthening our senior management team as we continue to execute a strategic plan to build long-term value for all of our stakeholders.” Dr. Wynne will oversee the product and formulation strategies and the growth of Gelteq's scientific team and v
Show less
Read more
Impact Snapshot
Event Time:
GELS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GELS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GELS alerts
High impacting Gelteq Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GELS
News
- Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel TechnologyGlobeNewswire
- Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug [Yahoo! Finance]Yahoo! Finance
- Gelteq Receives FDA Approval of its Suitability Petition for New Animal DrugGlobeNewswire
- Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor ConferenceGlobeNewswire
- Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand [Yahoo! Finance]Yahoo! Finance
GELS
Sec Filings
- 11/15/24 - Form 20-F
- 10/31/24 - Form NT
- 10/30/24 - Form 6-K
- GELS's page on the SEC website